Cinclus' severe erosive GERD candidate well tolerated in Phase I

Cinclus Pharma AG (Basel, Switzerland) said single and multiple ascending doses of oral X842 for five days were well tolerated in an open-label, Swedish Phase I trial in about 39 healthy volunteers. The company is developing the candidate to treat severe erosive gastroesophageal reflux disease (GERD)...